UTHR
United Therapeutics Corporation NASDAQ$570.40
After hrs
$581.22
+0.00%
Mkt Cap $27.3B
52w Low $272.12
88.8% of range
52w High $607.89
50d MA $540.24
200d MA $452.54
P/E (TTM)
18.9x
EV/EBITDA
11.0x
P/B
3.6x
Debt/Equity
0.0x
ROE
18.8%
P/FCF
20.7x
RSI (14)
—
ATR (14)
—
Beta
0.75
50d MA
$540.24
200d MA
$452.54
Avg Volume
527.0K
About
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | BMO | 7.13 | 7.70 | +8.0% | 473.43 | +1.4% | +13.0% | +6.4% | +6.4% | +8.5% | +5.3% | +10.4% | — |
| Oct 29, 2025 | BMO | 6.89 | 7.16 | +3.9% | 415.34 | +0.0% | +9.6% | +9.2% | +7.2% | +5.6% | +5.3% | +17.0% | — |
| Jul 30, 2025 | BMO | 7.29 | 6.41 | -12.1% | 297.56 | -4.0% | -5.2% | -7.7% | -1.1% | -1.7% | +2.4% | +2.4% | — |
| Apr 30, 2025 | BMO | 6.29 | 6.63 | +5.4% | 300.76 | +5.4% | +0.8% | -2.3% | -2.0% | -0.7% | -1.9% | +6.0% | — |
| Feb 26, 2025 | BMO | 6.40 | 6.19 | -3.3% | 357.50 | -3.9% | -10.8% | -9.5% | -10.5% | -13.3% | -13.7% | -14.1% | — |
| Oct 30, 2024 | BMO | 6.43 | 6.39 | -0.6% | 352.80 | +1.1% | +2.4% | +6.0% | +6.0% | +6.8% | +8.5% | +5.0% | — |
| Jul 31, 2024 | BMO | 6.40 | 5.85 | -8.6% | 337.54 | -5.0% | -7.2% | -2.9% | -2.9% | -3.5% | -4.6% | +7.7% | — |
| May 1, 2024 | BMO | 5.65 | 6.17 | +9.2% | 234.33 | +3.7% | +8.9% | +10.2% | +12.0% | +11.2% | +13.6% | +17.4% | — |
| Feb 21, 2024 | BMO | 4.19 | 4.36 | +4.1% | 214.16 | +2.6% | +2.3% | +1.6% | +6.0% | +4.4% | +5.9% | +11.1% | — |
| Nov 1, 2023 | BMO | 5.04 | 5.38 | +6.7% | 222.86 | -5.0% | +0.5% | +2.4% | +0.7% | +2.4% | +3.4% | +8.0% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $574.77 | $576.06 | +0.2% | -0.5% | +0.5% | +0.7% | +0.5% | +1.0% |
| Mar 31 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $588.36 | $583.62 | -0.8% | +0.8% | -3.1% | -4.0% | -4.9% | -3.9% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $588.36 | $583.62 | -0.8% | +0.8% | -3.1% | -4.0% | -4.9% | -3.9% |
| Mar 31 | BofA Securities | Maintains | Neutral → Neutral | — | $588.36 | $583.62 | -0.8% | +0.8% | -3.1% | -4.0% | -4.9% | -3.9% |
| Mar 30 | TD Cowen | Maintains | Buy → Buy | — | $522.83 | $605.22 | +15.8% | +12.5% | +13.4% | +9.1% | +8.0% | +7.0% |
| Mar 23 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $524.28 | $529.02 | +0.9% | -0.6% | +1.4% | +3.3% | +1.6% | -0.3% |
| Mar 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $544.71 | $539.84 | -0.9% | -2.2% | -1.6% | -1.9% | -0.9% | -2.6% |
| Mar 5 | UBS | Maintains | Buy → Buy | — | $490.21 | $490.00 | -0.0% | -1.1% | -2.5% | +7.9% | +9.3% | +11.1% |
| Feb 26 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $535.10 | $530.01 | -1.0% | -5.9% | -5.8% | -4.0% | -6.8% | -8.4% |
| Feb 26 | RBC Capital | Maintains | Outperform → Outperform | — | $535.10 | $530.01 | -1.0% | -5.9% | -5.8% | -4.0% | -6.8% | -8.4% |
Recent Filings
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Nebulized Tyvaso's positive Phase 3 results for IPF treatment validate United Therapeutics' pipeline and could drive significant revenue growth if approved, supporting stock appreciation.
Mar 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A new CPA executive appointment suggests improved financial controls and accounting rigor, which could enhance investor confidence and potentially support stock stability, particularly relevant for smaller-cap companies like SNBR and UTHR.
Mar 12
8-K · 1.01
!! High
United Therapeutics Corp -- 8-K 1.01: Material Agreement
United Therapeutics authorized a $2 billion share repurchase program and immediately entered into accelerated share repurchase agreements with Citibank, signaling management confidence and potentially supporting stock prices through reduced share count.
Mar 9
8-K · 7.01
! Medium
United Therapeutics Corp -- 8-K 7.01: Regulation FD Disclosure
United Therapeutics will host a webcast at 8:30 a.m. to present ADVANCE OUTCOMES trial results, potentially providing investors with significant clinical data regarding a key pipeline program.
Mar 2
8-K
Mannkind Corporation -- 8-K Filing
MannKind's Furoscix ReadyFlow Autoinjector will receive FDA review completion by July 26, 2026, potentially expanding its commercial portfolio and supporting future revenue growth if approved.
Feb 26
8-K
United Therapeutics Corp -- 8-K Filing
United Therapeutics achieved record $3.18 billion in 2025 revenues, representing 11% year-over-year growth, signaling strong commercial momentum across its product portfolio for investors.
Feb 25
Data updated apr 27, 2026 7:10am
· Source: massive.com